Stockpolly
Search
Delisting risk
AEMD · NASDAQ · Medical - Devices

Aethlon Medical (AEMD)

Developer of the investigational Hemopurifier for virus and extracellular-vesicle removal.

$1.71
Pre-market−0.13 (−7.07%)
At close$1.84(0.00%)
Watchlist

In millions of USD, except per-share figures

In millionsQ2 FY24Sep 2023Q3 FY24Dec 2023Q4 FY24Mar 2024Q1 FY25Jun 2024Q2 FY25Sep 2024Q3 FY25Dec 2024Q4 FY25Mar 2025Q1 FY26Jun 2025Q2 FY26Sep 2025Q3 FY26Dec 2025Q4 FY26Mar 2026Q1 FY27Jun 2026
Cost of revenue000000000000
Gross profit000000000000
342332221222
Research & development111000110110
33333211,2111121
Selling & marketing112111000000
General & administrative22111101,2110021
Other expenses−10−20000−1,21000−11
Operating income−3−4−2−3−3−2−2−2−2−2−2−2
000000−400000
Interest income000000000000
Interest expense000000000000
Other non-operating income0−11000400000
Income before tax−3−3−2−3−3−2−6−2−1−2−2−2
Net income from continuing operations−3−3−2−3−3−2−6−2−1−2−2−2
Net income−3−3−2−3−3−2−6−2−1−2−2−2
EPS, basic−$97.74−$110.19−$74.08−$27.58−$16.11−$10.05−$34.41−$8.49−$3.74−$2.45−$1.49−$4.02
EPS, diluted−$97.74−$110.19−$74.08−$27.58−$16.11−$10.05−$34.41−$8.49−$3.74−$2.45−$1.49−$4.02
Weighted average shares, basic000000000110
Weighted average shares, diluted000000000110
EBITDA−3−3−3−2−3−2−6−2−1−2−2−1
Depreciation & amortization000000000000
EBIT−3−3−3−3−3−2−6−2−1−2−2−2